ArticleVeterinary dermatology2026
Applying the Health Belief Model to Identify Factors Associated With Owner Persistence to Allergen-Specific Immunotherapy.
Article in Veterinary dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAllergen-specific immunotherapy (ASIT) is the only treatment targeting the pathophysiology of canine atopic dermatitis (cAD) and feline atopic skin syndrome (FASS). Despite its disease-modifying potential, owner persistence remains a clinical challenge. This study applied the Health Belief Model (HBM) to evaluate factors influencing owner persistence with ASIT. HYPOTHESIS/
objectivesWe hypothesised that owner perceptions of ASIT effectiveness, perceived barriers (e.g., cost) and ease of treatment integration would be associated with persistence. The objective was to identify modifiable psychological and logistical factors to support sustained ASIT use in cAD and FASS management. ANIMALS: No animals were used. MATERIALS AND
methodsPets prescribed ASIT between 1 January 2020 and 31 May 2024, were identified from four geographically diverse veterinary dermatology practices. Owners completed a survey assessing HBM constructs-perceived susceptibility, perceived severity, perceived benefits, perceived barriers, self-efficacy, social support-and a knowledge domain. Owner-reported ASIT refill behaviour served as a proxy for persistence. Associations between HBM constructs and refill behaviour were evaluated using chi-square tests and logistic regression.
resultsHigher perceived disease severity, greater perceived benefits and increased self-efficacy were positively associated with persistence. Owners who viewed their pet's condition as severe, believed ASIT effective, or felt confident administering treatment were more likely to continue therapy. Cost concerns and administration challenges were key perceived barriers. CONCLUSIONS AND CLINICAL RELEVANCE: This study highlights the psychological factors in owner persistence with ASIT. HBM-informed educational strategies that emphasise disease impact, treatment value and owner confidence may improve persistence with ASIT and long-term disease management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.